Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 14/20 | 0.55 |
| ▸ | CA2 | P00918 | 14/20 | 0.55 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24297067 | 0.93 | TDP1 (0.63) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL18970801 | 0.89 | TDP1 (0.51) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL917886 | 0.84 | TDP1 (0.64) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL28301448 | 0.84 | TDP1 (0.59) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL22829019 | 0.83 | TDP1 (0.57) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL28210550 | 0.82 | TDP1 (0.70) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL12282152 | 0.81 | TDP1 (0.56) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL3020258 | 0.81 | TDP1 (0.81) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL569251 | 0.81 | TDP1 (0.74) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL21494308 | 0.81 | TDP1 (0.64) | TDP1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-7056917-B2 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-06 | — | — | US | disclosed |
| US-20060106034-A1 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | TRINE PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| EP-1389463-A1 | MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-20030092720-A1 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092720-A1 | Drug efflux pump inhibitor | ABCB11, ABCB1, ABCC1 | TDP1 3884/4885CA1 4826/4885CA2 2865/4885 |
| US-20060106034-A1 | Drug efflux pump inhibitor | ABCB11, ABCB1, ABCC5 | TDP1 4124/4885CA1 4815/4885CA2 3193/4885 |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | ABCB11, ATP6AP1, HRH2 | TDP1 4794/4885CA1 4434/4885CA2 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.